"We are taking an already transformational approach used for blood cancers and modifying it for use in difficult-to-treat solid cancers," says Shahab Asgharzadeh, lead researcher on a $6 million grant from the California Institute for Regenerative Medicine to treat children and adolescents with recurrent solid tumors.
Asgharzadeh and his team at Children's Hospital Los Angeles have learned, chemotherapy and radiation provide less than a 30% overall survival rate for patients with sarcomas and neuroblastomas, which tend to reoccur in children and young adults after they've received chemo and radiation, per a press release.
That's why the researchers are working on using patients' own immune cells to target and kill the cancer cells instead of using the patient's own cells to do so.
"This CAR T-cell approach enhances the engineered immune cells, so they are not disabled once they enter the solid tumor environment, allowing them to better kill the cancer cells," Asgharzadeh says.
"This therapy offers an alternative to our young patients whose tumors have returned and who currently lack good therapeutic options," he adds.
The team plans to use a method called chimeric TGFB-signaling receptor (CTSR)-enabled anti-B7H3 CAR T-cell therapy
A customized collection of grant news from foundations and the federal government from around the Web.
In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.